Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover, Single-Centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Next Previous
Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover, Single-Centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 8309 (Primary)
  • Indications Chronic obstructive pulmonary disease; Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors AstraZeneca

Most Recent Events

  • 21 Feb 2011 New source identified and integrated (ISRCTN: Current Controlled Trials).
  • 21 Feb 2011 Actual end date changed from Oct 2009 to Dec 2010 as reported by ClinicalTrials.gov.
  • 29 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top